Search Results - "Barba Joaquin, Andres"

Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events by Alserawan, Leticia, Anguera, Geòrgia, Zamora Atenza, Carlos, Serra López, Jorgina, Martínez-Martínez, Laura, Riudavets Melià, Mariona, Sullivan, Ivana, Barba Joaquin, Andrés, Majem Tarruella, Margarita, Vidal, Silvia

“…Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a…”
Get full text

Brain metastases in colorectal cancer: prognostic factors and survival analysis by Del Carpio Huerta, Luis, Virgili Manrique, Anna Cristina, Szafranska, Justyna, Martin-Richard, Marta, Paez Lopez-Bravo, David, Sebio Garcia, Ana, Espinosa Mariscal, Iñigo, Gomila Pons, Paula, Andres Granyo, Marta, Barba Joaquin, Andres, Barnadas Molins, Agusti, Tobeña Puyal, Maria

“…Purpose Colorectal cancer (CRC) brain metastases (BM) are an uncommon and late event. We aim to investigate the impact of clinical factors, treatment…”
Get full text

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents by Zamora Atenza, Carlos, Anguera, Geòrgia, Riudavets Melià, Mariona, Alserawan De Lamo, Letícia, Sullivan, Ivana, Barba Joaquin, Andrés, Serra Lopez, Jorgina, Ortiz, M. Angels, Mulet, Maria, Vidal, Sílvia, Majem, Margarita

“…Background Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1…”
Get full text

Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors by Alserawan, Leticia, Mulet, Maria, Anguera, Geòrgia, Riudavets, Mariona, Zamora, Carlos, Osuna-Gómez, Rubén, Serra-López, Jorgina, Barba Joaquín, Andrés, Sullivan, Ivana, Majem, Margarita, Vidal, Silvia

“…Immune checkpoint inhibitors (ICI) have the potential to trigger unpredictable immune-related adverse events (irAEs), which can be severe. The underlying…”
Get full text